Tag: Parliamentary Question

  • David Anderson – 2016 Parliamentary Question to the Department of Health

    David Anderson – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by David Anderson on 2016-10-07.

    To ask the Secretary of State for Health, what assessment he has made of the potential effect of the expansion of the Doctaly scheme on patients’ access to GP services.

    David Mowat

    The Department has made no assessment of the potential effect of the expansion of the Doctaly scheme on patients’ access to general practice (GP) services.

    The General Practice Forward View, published in April 2016, announced that an extra £2.4 billion a year will be invested in GP services by 2020/21. As part of overall investment in general practice, NHS England will provide over £500 million of recurrent funding by 2020/21, on top of current primary medical care allocations, to enable clinical commissioning groups to commission and fund extra capacity across England. This is to ensure that by 2020, everyone has access to GP services, including sufficient routine appointments at evenings and weekends to meet locally determined demand, alongside effective access to out of hours and urgent care services.

  • Lord Hunt of Kings Heath – 2015 Parliamentary Question to the Department of Health

    Lord Hunt of Kings Heath – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Hunt of Kings Heath on 2015-11-19.

    To ask Her Majesty’s Government what assessment they have made of the effectiveness of bevacizumab in the treatment of age-related macular degeneration.

    Lord Prior of Brampton

    No assessment by the Government has been made on the effectiveness of bevacizumab (Avastin) in the treatment of wet age-related macular degeneration (AMD) as there are two other effective, licensed treatments for wet AMD which have been recommended by the National Institute for Health and Care Excellence. Bevacizumab is not licensed for use in the treatment of wet AMD.

  • Andy Slaughter – 2016 Parliamentary Question to the Ministry of Justice

    Andy Slaughter – 2016 Parliamentary Question to the Ministry of Justice

    The below Parliamentary question was asked by Andy Slaughter on 2015-12-17.

    To ask the Secretary of State for Justice, for what reason Community rehabilitation companies workforce information report: Q2 2015 to 2016 statistics were cancelled for release.

    Andrew Selous

    The Community Rehabilitation Company (CRC) Workforce Information Report provided information on staffing within the CRCs when they were under public sector management. The final edition was published on 26 February 2015 and provided information as at 31 December 2014. The 21 CRCs became private companies on 1 February 2015 and are therefore now responsible for the management of their own staffing levels. At that time future editions of the Workforce Information Report, for which publication had been pre-announced, were cancelled.

  • Oliver Dowden – 2016 Parliamentary Question to the Department for Communities and Local Government

    Oliver Dowden – 2016 Parliamentary Question to the Department for Communities and Local Government

    The below Parliamentary question was asked by Oliver Dowden on 2016-01-27.

    To ask the Secretary of State for Communities and Local Government, what guidance his Department issues to local authorities on (a) a Local Development Order and (b) Supplementary Planning Guidance to facilitate alternative, less intrusive development on a specific location in the Green Belt where there is already extant planning permission for development in that location.

    Brandon Lewis

    An extant planning permission does not prevent consideration of a further planning application for the same site. It would be for the local authority to assess each proposal on its merits, in the light of all material considerations, including the protections for Green Belt set out in our National Planning Policy Framework. If the development proposed would be inappropriate in Green Belt, the Framework states that planning permission should generally be refused. However, if the local authority finds that any harms caused by the development would be clearly outweighed by other considerations, and that very special circumstances justify planning permission, permission may be granted. If necessary the local authority can impose planning conditions or require design changes to mitigate any adverse impact.

    A Local Development Order or Supplementary Planning Guidance would also have to be designed by the local authority to accord with policies in the Framework, including the need to protect the openness of Green Belt land.

  • Andrew Gwynne – 2016 Parliamentary Question to the Ministry of Justice

    Andrew Gwynne – 2016 Parliamentary Question to the Ministry of Justice

    The below Parliamentary question was asked by Andrew Gwynne on 2016-02-19.

    To ask the Secretary of State for Justice, what discussions his Department has had with burial authorities and other stakeholders on the reuse of graves.

    Caroline Dinenage

    The issue of burial space is regularly discussed at meetings of the Burial and Cremation Advisory Group, which is chaired by this department and comprises key stakeholders and representatives within government and the wider burial sector. In addition, the department regularly engages on the issue with individual stakeholders, as appropriate.

  • Louise Haigh – 2016 Parliamentary Question to the Cabinet Office

    Louise Haigh – 2016 Parliamentary Question to the Cabinet Office

    The below Parliamentary question was asked by Louise Haigh on 2016-03-15.

    To ask the Minister for the Cabinet Office, when he expects the report on electoral fraud by the Government’s Anti-Corruption Champion to be published.

    John Penrose

    Sir Eric Pickles will make his recommendations as soon as he is able. 66 written submissions are under consideration, as well as evidence provided in meetings with specific people and at a seminar of academics, stakeholder organisations and political parties.

  • David Morris – 2016 Parliamentary Question to the HM Treasury

    David Morris – 2016 Parliamentary Question to the HM Treasury

    The below Parliamentary question was asked by David Morris on 2016-04-15.

    To ask Mr Chancellor of the Exchequer, whether he has made an assessment as to how much the abolition of class 2 national insurance contributions will save on average for each self-employed person; and if he will make a statement.

    Mr David Gauke

    The abolition of Class 2 NICs means that 3.4 million self-employed individuals will gain by an average of £134 in 2018-19 when Class 2 National Insurance contributions are abolished. This will allow millions of self-employed individuals to keep more of their money and invest it back into growing their business, as well as ending an outdated and complex feature of the NICs system.

  • Oliver Colvile – 2016 Parliamentary Question to the Department of Health

    Oliver Colvile – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Oliver Colvile on 2016-05-24.

    To ask the Secretary of State for Health, for what reasons people in Plymouth who have epilepsy are waiting six months from having a seizure to see a consultant of specialist nurse.

    Jane Ellison

    There are no national measures or means by which the Department monitors frequency of patients reviews, either by consultants or nurses. Guidance is issued by the National Institute for Health and Care Excellence however this does not replace the skills and knowledge of health professionals in managing patients. The arrangements for the management and follow up of people with epilepsy are a local matter and decisions on the frequency with which patients are seen should be made on a case by case basis, taking into account the individual circumstances of each patient.

    NHS England advises that the maximum wait for outpatients to receive a neurology appointment is 12 weeks currently. Additionally 92% of patients are being seen under the specified ‘Referral To Treatment’ waiting times of 18 weeks which is within the national target.

    The information on the number of people with epilepsy in Plymouth is not available in the format requested.

  • Baroness Kinnock of Holyhead – 2016 Parliamentary Question to the Foreign and Commonwealth Office

    Baroness Kinnock of Holyhead – 2016 Parliamentary Question to the Foreign and Commonwealth Office

    The below Parliamentary question was asked by Baroness Kinnock of Holyhead on 2016-07-11.

    To ask Her Majesty’s Government whether the South Sudan Troika plans to issue a comprehensive statement on its priorities in Sudan and South Sudan.

    Baroness Anelay of St Johns

    The UK, along with our Troika partners (the United States and Norway), has been active in supporting efforts to resolve the crisis in South Sudan. This includes working with the Inter-Governmental Authority on Development and regional partners.

    We are deeply concerned about the recent fighting and will continue to work with our troika and regional partners to resolve the crisis.

  • Marie Rimmer – 2016 Parliamentary Question to the Department of Health

    Marie Rimmer – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Marie Rimmer on 2016-10-07.

    To ask the Secretary of State for Health, with reference to the report of the Independent Cancer Taskforce, Achieving world-class cancer outcomes: A strategy for England 2015-2020, published in July 2015, what progress has been made on implementation of recommendation 47 on NHS England commissioning NICE to develop updated guidelines for adjuvant treatment for breast cancer.

    Nicola Blackwood

    The National Institute for Health and Care Excellence’s (NICE) guideline on early and locally advanced breast cancer: diagnosis and management (CG80) recommends the use of adjuvant bisphosphonates for the management of breast cancer treatment-induced bone loss in specified clinical circumstances. This guideline is currently being updated and the use of adjuvant bisphosphonates has been identified as one of the key areas that will be covered in this update. NICE expects to publish its updated guideline in July 2018.